event-free survival

event-free survival

Failure-free survival Oncology The timespan that follows therapy for a malignancy or other dread disease, during which there are no objective signs of recurrence
References in periodicals archive ?
Event-free survival rates were 22% and 44.2%, respectively.
The primary endpoint is event-free survival. Analysis of the primary endpoint will be triggered upon reaching a prespecified target number of events.
The efficacy of Sprycel tablets in combination with chemotherapy was evaluated in a single cohort of the Phase 2, multicenter, single-arm CA180-372 study, which included 78 pediatric patients with newly diagnosed B-cell precursor Ph+ ALL.1,2 At three years, the study demonstrated an event-free survival binary rate of 64.1% (95% confidence interval [CI]: 52.4 to 74.7).
Other secondary endpoints included number of patients with adverse events, time to treatment failure, event-free survival, time to next anti-lymphoma treatment, time to next chemotherapy treatment, overall response rate at 120 weeks based on International Working Group (IWG) 1999 criteria, and health-related quality of life as measured by the EORTC QLQ-C30.
The main aim of the trial is to analyse safety, additional endpoints including mobilisation of acute myeloid leukaemia blasts, effect on neutropenia, time to and duration of remission, evaluation of event-free survival and evaluation of the overall survival probability at six- and 12-months.
the adult oncology Cancer and Leukemia Group B showed a 63% event-free survival rate at 7 years for those treated in pediatric centers, compared with just 34% in those treated in adult settings (Blood 2008; 112:1646-54).
Treatment for childhood acute lymphoblastic leukemia (ALL) has reached a five-year event-free survival rate of more than 80%.
A retrospective study of 321 ALL patients, aged 16-20 years, participating in clinical trials conducted by the Children's Cancer Group versus the adult oncology Cancer and Leukemia Group B showed a 63% event-free survival rate at 7 years for those treated in pediatric centers compared with just 34% in those treated in adult settings (Blood 2008;112:1646-54).
In women with estrogen receptor-positive tumors, 8-year recurrence-free survival was 86% with surgery 92% with surgery plus 5 years of tamoxifen, and 94% with surgery tamoxifen, and chemotherapy Event-free survival was 74% with surgery 82% with the addition of tamoxifen, and 88% with surgery tamoxifen, and chemotherapy.
Results from the CA180-372 trial presented at the 2017 American Society of Hematology Annual Meeting showed that at three years, the combination of Sprycel and chemotherapy demonstrated an event-free survival rate, the study's primary endpoint, of 65.5%, and an overall survival rate of 91.5%.
In a clinical study, AVXS-101 showed life-saving efficacy, with all 15 infants treated event free at 20 months compared with an event-free survival rate of 8 percent in an historical cohort (NEJM, November 2017).
They found that the five-year event-free survival rates increased 12% in the group with the rapid 10-day technique.

Full browser ?